HAT1 and melanoma: On the other hand, Bugide et al. recently demonstrated that the BRAFV600E melanoma cells treated with a BRAF inhibitor (BRAFi) downregulate the expression of HAT1, and by employing NanoString-based nCounter PanCancer Pathway Panel-based gene expression analysis, they found that the MAPK, Ras, transforming growth factor (TGF)-β and Wnt pathways are activated [57].